The Lumanity team (then “BresMed”) supported the first successful HTA submissions to NICE in CAR T-cell therapy, and years on from the first approval, access to these innovative new therapies has expanded markedly. To help understand how countries currently evaluate established novel therapies, we have produced a whitepaper examining the primary factors that drive reimbursement decisions for CAR T-cell therapy across the US, UK and EU4 (France, Germany, Italy and Spain).
Fill out the form on the right to download the paper
Download the pdf
"*" indicates required fields